tiprankstipranks
Trending News
More News >

Syndax publishes AUGMENT-101 trial data in Blood

Syndax (SNDX) announced that data from the pivotal Phase 2 portion of the AUGMENT-101 trial of revumenib, a menin inhibitor, in patients with relapsed or refractory mutant NPM1 acute myeloid leukemia have been published in Blood.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

1